Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for spasticity in progressive multiple sclerosis
2011-002258-30Phase 3Completed
- Sponsor
- Almirall
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cannabidiol in multiple sclerosis (MS) (2 arms), sponsored by Almirall. Primary endpoint: Change in H/M ratio at week 4. Started Apr 2012; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2011-002258-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002258-30.